W ang et al 1 recently showed that in patients with transient ischemic attack (TIA) or minor stroke that can be treated within 24 hours after the onset of symptoms, the combination of clopidogrel and aspirin was superior to aspirin alone for reducing the risk of stroke in the first 90 days, without increasing the risk of hemorrhage. We report a patient treated with this combination but suffered recurrent stroke and hemorrhage.
A 49-year-old male presented with acute onset of right limb weakness and hypoesthesia for 1 hour before admitted to hospital with a National Institute of Health Stroke Scale (NIHSS) score of 2. The patient had no history of hypertension or coronary artery disease, but smoked 1 pack per day for 10 years and had hyperlipidemia. Computed tomography (CT) of 2 hours after symptom onset was negative ( Figure 1A ) and magnetic resonance imaging (MRI) on the second day ( Figure 1B ) showed left frontal lobe cerebral infarction. Computed tomography angiogram (CTA) revealed left internal carotid artery stenosis. Blood routine, liver function, renal function and coagulation function examination were normal. Four hours after stroke onset, he was prescribed 300 mg of aspirin combined with 75 mg of clopidogrel for 16 days, and 100 mg of aspirin plus 75 mg of clopidogrel for another 8 days. During the treatment, the patient's muscle strength in his right lower limb improved from 1/5 to 4/5. However, on the last day of treatment, the patient experienced sudden onset of right limb weakness (0/5) again with aphasia, which subsided after 3 hours. On the evening of the following day, patient suffered recurrent right limb weakness (0/5) and aphasia. CT ( Figure 1C ) showed left frontal lobe hemorrhage and a new infarction in the left basal ganglia and corona radiata. CTA showed occlusion of the left middle cerebral artery ( Figure 1D ). MRI confirmed infarction in the left basal ganglia, left parietal lobe and insular cortex ( Figure 1E ).
The CHANCE study (clopidogrel in high-risk patients with acute non-disabling cerebrovascular events) showed that 3 months of treatment with a combination of clopidogrel and aspirin as compared to aspirin alone, could further reduce the risk of recurrent stroke without increasing the risk of hemorrhage among patients who suffered acute high-risk TIA or minor ischemic stroke. 1 Our patient met the following inclusion criteria of CHANCE study: age of 40 years or older; diagnosis of an acute minor ischemic stroke or TIA (score 3 or less); and ability to start the study drug within 24 hours after symptom onset. Apparently, dual anti-platelet treatment may have increased the risk of cerebral hemorrhage in our patient and did not prevent the recurrence of cerebral infarction. Although the dose of aspirin for our patient was higher than that used in the CHANCE study which may increase the risk of hemorrhage, our patient took dual anti-platelet treatment for only 24 days, far less than 90 days of the CHANCE study. So we suggest the efficacy and safety of combination of clopidogrel and aspirin need reevaluation before safe application.
Previous studies have discussed the efficacy and safety of dual anti-platelet treatment in the prevention of ischemic events. The CHARISMA (clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance) study 2 showed that combination of clopidogrel and aspirin in patients with established coronary, cerebral, or peripheral arterial disease or in patients with multiple risk factors for atherothrombosis who have not sustained an ischemic event is not superior to aspirin alone in the prevention of myocardial infarction, stoke or vascular death. However, the dual antiplatelet therapy group had higher rate of bleeding than the other group. The MATCH (aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients) study 3 demonstrated that the benefit of combination treatment over clopidogrel alone in reducing the risk of ischemic events after TIA or stroke was small, while the risk of major or life-threatening bleeding on aspirin plus clopidogrel was higher. The FASTER (fast assessment of stroke and transient ischemic attack to prevent early recurrence) study 4 showed that despite the reduction of risk for subsequent stroke in high-risk patients immediately after TIA or minor stroke, the hemorrhagic risk of the combination of aspirin and clopidogrel outweighed this potential benefit. All of these studies seemed to suggest that the combination of aspirin and clopidogrel can increase the risk of intracerebral hemorrhage.
Despite the promising results demonstrated by the CHANCE study, our experience suggests that dual anti-platelet therapy may increase the risk of cerebral hemorrhage and should be evaluated in more randomizedcontrolled trials before safe application.
